Multichannel
Five eye-openers from the MIT Healthcare Panel
Modern pharma should not underestimate the importance of experience and culture in this age of innovation in R&D and data science
More Articles
Access and Evidence
Prescription drug pricing: The times they are a changin’
The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value
Commercial
Has direct to consumer marketing in pharma had its day?
Outmoded and cliched DTC campaigns may be harming not helping pharma in the US
Clinical
Clinical must think outside, and inside the box
From site-in-a-box to virtual/siteless trials: which new model will successfully disrupt clinical research?
Multichannel
The online health trends pharma should be tapping into
Pharma should be harnessing some powerful online trends but is it?
Medical
Taking the plunge into digital
Medical affairs is starting to expand its knowledge, reach and engagement with digital tools
Access and Evidence
Putting a price on life: Is the answer outside pharma?
Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.
Commercial
Breaking out of data silos in commercial
Pharma’s commercial teams have much to gain if they can overcome technical and cultural blockages that prevent data sharing
Patients and Medical
Empowering patients with the right data at the right time
Pharma is starting to exploit the potential of data from connected devices and smartphones to help patients better manage their conditions
Patients and Medical
Five shifts toward consumer-centric transformation
There's now a roadmap for pharma organisations seeking to become truly patient centred